Savings Effect

ETERNAL: CO BROADLY AGREED WITH AN ANALYST'S CALCULATION THAT IMPLIED A 3% TO 3.5% QUICK COMMERCE MARGIN, BASED ON A $1 BILLION EBITDA TARGET BY FY29 AND A 60% QUICK COMMERCE NOV CAGR. ETERNAL: CO IS ON TRACK FOR 3,000 DARK STORES BY MARCH, WITH STORE EXPANSION IMPLIED BY THE 60% CAGR, AND THE MIX OF DARK STORES IS CHANGING TOWARDS GEOGRAPHIC DIVERSIFICATION.

AYE FINANCE: CO EXPECTS FY '27 GROWTH IN THE RANGE OF 25% TO 30% AND TARGETS A RETURN ON ASSETS (ROA) OF 4% TO 4.5%. CREDIT COSTS ARE EXPECTED TO NORMALIZE TO 3.5% TO 4% FOR FY '27, WITH A LONG-TERM TARGET OF 3.25% TO 3.75%. - CONCALL UPDATE

PUNJAB & SIND BANK: CO PLANS TO RAISE RS 3000 CR THROUGH STAKE SALE || CO AIMS TO ACHIEVE BUSINESS OF RS 4 LAKH CR BY END OF FY29 - BL

Infosys, Accenture lead LinkedIn’s 2026 list of top companies for career growth in India

ShyamMetalics proposes ₹2,700 crore expansion plan Company to invest ₹900 crore in Special Bar Quality (SBQ) and Specialty Wire Rod & Bar Mill Stainless steel capacity to be expanded by ₹1,800 crore

Bandhan Bank: Guidance - Concall Update Management aims for a Return on Assets (ROA) of 1.6% to 1.7% by the exit of FY27, with sequential improvement. Net Interest Margin (NIM) is expected to improve by another 10 to 20 basis points over the next two to three quarters. The credit cost guidance is 1.6% to 1.7% by the exit of FY27, with expected improvement from current levels. The bank aims for credit growth of around 14% to 15%, with an endeavor for better deposit growth. The target for the secured book mix of 58% by FY27 exit has been nearly achieved, currently at 56%.

#ShyamMetalics proposes ₹2,700 crore expansion plan Company to invest ₹900 crore in Special Bar Quality (SBQ) and Specialty Wire Rod & Bar Mill Stainless steel capacity to be expanded by ₹1,800 crore

Go Digit General Insurance: Guidance - Concall Update Management explicitly stated they do not provide formal guidance, as their experience shows market dynamics make such projections unreliable. They personally feel that new specialized commercial lines could generate approximately INR1,000 crore in premium over the next three to five years. The company previously expected leverage to reach about 5% over the next two years, a target that has now been achieved. They aim for equity asset allocation to reach 10% and could comfortably increase it to 12.5% given their strong solvency. Management expressed strong optimism for industry growth over the next two years, driven by new international norms and standardization.

Teva has received final US FDA approval for Symbicort (Budesonide; Formoterol Fumarate Dihydrate) Alert: #Cipla is amongst one of the filers in this drug

EmcurePharma Large Trade | 18 Lk Shares (0.94% Eq) Worth Rs 289.5 Cr Change Hands At Rs 1,608/sh In Block Deal Window

DR. REDDY'S LAB: DELHI HC WARNS CO OVER ‘OLYMVIQ’ TRADEMARK || COURT ASKED CO TO FILE A FRESH UNDERTAKING DETAILING THE STATUS OF COMPLIANCE SINCE THE 30 MARCH ORDER, WHICH HAD ASKED THE HYDERABAD-BASED CO TO DISCONTINUE THE USE OF THE OLYMVIQ NAME FOR ITS WEIGHT-LOSS DRUG AND TRANSITION TO OLYMRA. - MINT

TANFAC INDUSTRIES: CO SECURES LONG-TERM BLUE STAR SUPPLY AGREEMENT WORTH RUPEES 61 CRORE ANNUALLY, STRENGTHENING SPECIALTY CHEMICALS REVENUE VISIBILITY